TY - JOUR
T1 - Vaginal clear cell adenocarcinoma in the United States
AU - Trimble, Edward L.
AU - Rubinstein, Lawrence V.
AU - Menck, Herman R.
AU - Hankey, Benjamin F.
AU - Kosary, Carol
AU - Giusti, Ruthann M.
PY - 1996/4
Y1 - 1996/4
N2 - We elected to examine available information from several sources to approximate the annual number of cases of vaginal adenocarcinoma in the United States for recent years. Data were obtained from the Registry on Hormonal Transplacental Carcinogenesis, the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute, the National Cancer Databank of the American College of Surgeons Commission on Cancer, and a survey of gynecologic oncologists practicing in the United States. In 1990 a total of 33 new cases and 11 recurrences were reported, while in 1991 23 new cases and 8 recurrences were reported. Neither SEER nor the Registry appear to provide adequate surveillance for this rare disease. Phase III clinical trials are not feasible, given the small number of patients. Statistically effective phase II one-armed studies to investigate new agents in the treatment of advanced or recurrent vaginal clear cell cancer may be possible. Effective mobilization of patients and physicians will be required for such trials to be completed in a timely manner.
AB - We elected to examine available information from several sources to approximate the annual number of cases of vaginal adenocarcinoma in the United States for recent years. Data were obtained from the Registry on Hormonal Transplacental Carcinogenesis, the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute, the National Cancer Databank of the American College of Surgeons Commission on Cancer, and a survey of gynecologic oncologists practicing in the United States. In 1990 a total of 33 new cases and 11 recurrences were reported, while in 1991 23 new cases and 8 recurrences were reported. Neither SEER nor the Registry appear to provide adequate surveillance for this rare disease. Phase III clinical trials are not feasible, given the small number of patients. Statistically effective phase II one-armed studies to investigate new agents in the treatment of advanced or recurrent vaginal clear cell cancer may be possible. Effective mobilization of patients and physicians will be required for such trials to be completed in a timely manner.
UR - http://www.scopus.com/inward/record.url?scp=0029921928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029921928&partnerID=8YFLogxK
U2 - 10.1006/gyno.1996.0107
DO - 10.1006/gyno.1996.0107
M3 - Article
C2 - 8626097
AN - SCOPUS:0029921928
SN - 0090-8258
VL - 61
SP - 113
EP - 115
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -